Intellectus Partners LLC Has $355,000 Stock Holdings in Smith & Nephew plc (NYSE:SNN)

Intellectus Partners LLC lifted its stake in shares of Smith & Nephew plc (NYSE:SNN) by 21.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,030 shares of the medical equipment provider’s stock after purchasing an additional 2,269 shares during the period. Intellectus Partners LLC’s holdings in Smith & Nephew were worth $355,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the company. CWM LLC lifted its stake in Smith & Nephew by 68.6% in the 4th quarter. CWM LLC now owns 954 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 388 shares during the last quarter. Allworth Financial LP lifted its position in shares of Smith & Nephew by 1,566.2% in the third quarter. Allworth Financial LP now owns 1,133 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 1,065 shares during the last quarter. GAMMA Investing LLC bought a new position in shares of Smith & Nephew during the 4th quarter worth approximately $53,000. Signaturefd LLC increased its holdings in shares of Smith & Nephew by 31.3% during the 3rd quarter. Signaturefd LLC now owns 5,322 shares of the medical equipment provider’s stock worth $132,000 after acquiring an additional 1,268 shares during the last quarter. Finally, Seed Wealth Management Inc. acquired a new stake in Smith & Nephew during the fourth quarter worth approximately $213,000. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 15th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Smith & Nephew has a consensus rating of “Moderate Buy”.

Smith & Nephew Price Performance

Shares of NYSE SNN opened at $24.45 on Monday. The business has a fifty day moving average price of $25.99 and a two-hundred day moving average price of $26.00. The company has a quick ratio of 0.72, a current ratio of 1.77 and a debt-to-equity ratio of 0.44. Smith & Nephew plc has a fifty-two week low of $21.52 and a fifty-two week high of $33.08.

Smith & Nephew Announces Dividend

The company also recently announced a semi-annual dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Tuesday, April 2nd will be given a $0.462 dividend. This represents a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, April 1st.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.